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Interleukin-2/interferon-a2a/13-retinoic acid-based
chemoimmunotherapy in advanced renal cell carcinoma: results
of a prospectively randomised trial of the German Cooperative
Renal Carcinoma Chemoimmunotherapy Group (DGCIN)
J Atzpodien*,1,17,18, H Kirchner2, U Rebmann3, M Soder4, U Gertenbach5, M Siebels6, J Roigas7, R Raschke8,
S Salm9, B Schwindl10, SC Mu¨ller11, S Hauser11, C Leiber12, E Huland13, H Heinzer13, S Siemer14, B Metzner15,
H Heynemann16, P Fornara16, M Reitz17 and DGCIN – German Cooperative Renal Carcinoma
Chemoimmunotherapy Trials Group
1Fachklinik Hornheide an der Universita¨t Mu¨nster, Internistische Onkologie, Dorbaumstr. 300, Mu¨nster 48157, Germany; 2Klinikum Hannover Siloah,
Ha¨matologie/Onkologie, Roesebeckstr. 15, Hannover 30449, Germany; 3Krankenhaus der Anhaltischen Diakonissenanstalten, Klinik fu¨r Urologie,
Gropiusallee 3, Dessau 06846, Germany; 4Universita¨tsklinikum Heidelberg, Urologische Klinik, Im Neuenheimer Feld 110, Heidelberg 69120, Germany;
5Allgemeines Krankenhaus der Stadt Hagen, Urologische Klinik, Gru¨nstr. 35, Hagen 58095, Germany; 6Ludwig-Maximilians-Universita¨t Mu¨nchen,
Urologische Klinik, Marchioninistr. 15, Mu¨nchen 81377, Germany; 7Charite´ Berlin, Urologische Klinik, Schuhmannstr. 20-21, Berlin 10098, Germany;
8Klinikum Ernst-von-Bergmann, Urologische Klinik, Charlottenstr. 72, Potsdam 14467, Germany; 9Krankenhaus der Barmherzigen Bru¨der, Urologische
Abteilung, Nordallee 1, Trier 54292, Germany; 10Klinikum Weiden, Urologische Klinik, So¨llnerstr. 16, Weiden 92637, Germany; 11Medizinische
Einrichtungen der Universita¨t Bonn, Urologische Klinik, Sigmund-Freud Str. 25, Bonn 53105, Germany; 12Universita¨tsklinikum Freiburg, Urologische
Abteilung, Hugstetter Str. 55, Freiburg 79106, Germany; 13Universita¨tsklinikum Eppendorf, Urologische Klinik, Martinistr. 52, Hamburg 20246, Germany;
14Universita¨tsklinik Homburg, Urologische Klinik, Oskar-Orth-Str., Homburg/Saar 66421, Germany; 15Sta¨dtische Kliniken Oldenburg, Ha¨matologie/
Onkologie, Dr.-Eden-Str. 10, Oldenburg 26113, Germany; 16Universita¨tsklinikum der, Martin-Luther-Universita¨t Halle-Wittenberg, Urologische Klinik,
Ernst-Grube-Str. 40, Halle/Saale 06120, Germany; 17Europa¨isches Institut fu¨r Tumor Immunologie und Pra¨vention, Bonn 53175, Germany
We performed a prospectively randomised clinical trial to compare the efficacy of four subcutaneous interleukin-2-(sc-IL-2) and sc
interferon-a2a (sc-IFN-a2a)-based outpatient regimens in 379 patients with progressive metastatic renal cell carcinoma. Patients with
lung metastases, an erythrocyte sedimentation ratep70 mm h1 and neutrophil counts p6000ml1 (group I) were randomised to
arm A: sc-IL-2, sc-IFN-a2a, peroral 13-cis-retinoic acid (po-13cRA) (n¼ 78), or arm B: arm A plus inhaled-IL-2 (n¼ 65). All others
(group II) were randomised to arm C: arm A plus intravenous 5-fluorouracil (iv-5-FU) (n¼ 116), or arm D: arm A plus
po-Capecitabine (n¼ 120). Median overall survival (OS) was 22 months (arm A; 3-year OS: 29.7%) and 18 months (arm B; 3-year
OS: 29.2%) in group I, and 18 months (arm C; 3-year OS: 25.7%) and 16 months (arm D; 3-year OS: 32.6%) in group II. There were
no statistically significant differences in OS, progression-free survival, and objective response between arms A and B, and between
arms C and D, respectively. Given the known therapeutic efficacy of sc-IL-2/sc-INF-a2a/po-13cRA-based outpatient
chemoimmunotherapies, our results did not establish survival advantages in favour of po-Capecitabine vs iv-5-FU, and in favour of
short-term inhaled-IL-2 in patients with advanced renal cell carcinoma receiving systemic cytokines.
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The prognosis of metastatic renal carcinoma remains poor.
Although this tumour is highly resistant to chemotherapy and
hormone therapy, promising results have been reported with the
use of molecular agents that is, recombinant cytokines, notably
recombinant interleukin-2 (IL-2) and interferon-a (IFN-a), given
intravenously, subcutanously alone or in combination in out-
patient regimens with objective response rates between 6 and 31%
(Rosenberg et al, 1987; Atzpodien et al, 1990; Sleijfer et al, 1992;
Jayson et al, 1998; Tourani et al, 2003).
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When the present trial was planned, various studies focused on
the combination of immunmodulator substances and chemo-
therapeutic agents to increase antitumour activity. In preliminary
reports on oral 13-cis-retinoic acid (po-13cRA), a cell differentia-
tion regulator, po-13cRA could enhance antitumour efficacy in IL-
2/IFN-a- or chemoimmunotherapy-treated metastatic renal cell
carcinoma patients, with objective response rates between 17 and
42% (Atzpodien et al, 1995; Stadler et al, 1998). In the presence of
pulmonary metastases, locoregional administration of inhaled-IL-2
was reported to yield low toxicity combined with objective
response rates of pulmonary disease of 2.5–21% (Lorenz et al,
1996; Merimsky et al, 2004). Other reports showed that
the combination of cytokines with intravenous 5-fluorouracil
(iv-5-FU) could increase objective response rates to between 12
and 39% (van Herpen et al, 2000; Atzpodien et al, 2001, 2004).
Preliminary results of a phase II study combining IL-2/IFN-a with
oral Capecitabine, which is converted to 5-FU in vivo, reported
objective response rates of 34% (Oevermann et al, 2000).
Here, we prospectively compared the long-term therapeutic
efficacy of four outpatient combination regimens: arm A (sc-IL-2,
sc-IFN-a2a, po-13cRA) and arm B (arm A plus inhaled-IL-2) in
patients with pulmonary disease, and arm C (arm A plus iv-5-FU)
and arm D (arm A plus po-Capecitabine) in all others.
PATIENTS AND METHODS
Patients
Three hundred and seventy-nine patients with metastastic renal
cell carcinoma were stratified into two groups (Figure 1). Group I
patients (n¼ 143) were subsequently randomised to arm A (sc-IL-
2, sc-IFN-a2a, po-13-cRA) or arm B (arm A plus inhaled-IL-2),
whereas group II patients (all others; n¼ 236) were randomised to
arm C (arm A plus iv-5-FU) or arm D (arm A plus po-
Capecitabine). Median follow-up of these patients was 18 months
(range 0 –83 months). Patient pretreatment included radical
tumour nephrectomy (n¼ 343), radiotherapy (n¼ 51), chemo-
therapy (n¼ 11), immunotherapy (n¼ 18), chemoimmunotherapy
(n¼ 19), naturopathic therapy (n¼ 2), and others (n¼ 7) (Table 1).
Criteria for entry into the trial were as follows: histologically
confirmed progressive and irresectable metastatic renal cell
carcinoma; an expected survival duration of more than 3 months;
Karnofsky performance status 480%; age between 18 and 80
years; white blood cell count 43500ml1; platelet count
4100 000 ml1; haematocrit 430%; serum bilirubin, and creati-
nine o1.25 of the upper normal limit; no evidence of congestive
heart failure, no severe coronary artery disease, no cardiac
arrhythmias, no clinically symptomatic CNS disease or seizure
disorders, no human immunodeficiency virus infection, no
evidence of chronic active hepatitis, no concomitant corticosteroid
therapy. In all patients treated, no chemotherapy or immuno-
modulatory treatment had been performed during the previous 4
weeks. Also, pregnant and lactating women were excluded.
Treatment was approved by the institutional review board,
written informed consent was obtained from all patients before
entry into the trial. Fifty-four participating centres entered a total
of 379 eligible patients into this trial.
Treatment design
Patients were stratified into two groups according to the clinical
characteristics adapted from Lopez-Ha¨nninen et al (1996). Group I
consisted of patients with lung metastases, an erythrocyte
sedimentation rate p70 mm h1, and neutrophil counts
p6000 ml1; group II included all other patients. As all treatment
regimens were designed to be administered in the outpatient
setting, this required selection of patients with good or fair
performance status. Upon written receipt of patient pre-treatment
evaluation, per centre block randomisation was performed to rule
out centre-related statistical bias. Patients stratified to group I or II
were randomised according to a per centre 1 : 1 randomisation.
Group I patients received arm A (sc-IL2, sc-IFN-a2a, po-13-cRA)
or arm B (arm A plus inhaled-IL-2), whereas group II patients
received either arm C (arm A plus iv-5-FU) or arm D (arm A plus
po-Capecitabine).
Regimens
Treatment arm A consisted of sc-IFN-a2a (Roferon, Hoffmann-La
Roche, Grenzach-Wyhlen, Germany) (5 106 IU m2, day 1, weeks
1þ 4; days 1, 3, 5, weeks 2–3; 10 106 IU m2, days 1, 3, 5, weeks
5–8), sc-IL-2 (Proleukin, Chiron, Emeryville) (10 106 IU m2,
twice daily, days 3– 5, weeks 1þ 4; 5 106 IU m2, days 1, 3, 5,
weeks 2þ 3), and po-13cRA (20 mg 3 daily) over 8 weeks.
Treatment arm B consisted of treatment arm A combined with
inhaled-IL-2 (Proleukin, Chiron, Emeryville) (9 106 IU/2.5 ml
basic solution, four times a day, days 1–5, weeks 2þ 3 and weeks
5–8); the IL-2 (2 18 106 IU) was dissolved in 10 ml 5% glucose
solution, out of which 2.5 ml (9 106 IU IL-2 in solution) was
taken for each of the four daily administrations; IL-2 was inhaled
using a Salvia Lifetec Jetair inhalator (Kronberg, Germany)
constantly providing 3 mm particles. Treatment arm C consisted
of arm A plus iv-5-FU (1000 mg m2, day 1, weeks 5–8). Treatment
arm D consisted of treatment arm A combined with po-
Capecitabine (1000 mg m2 twice daily, days 1– 5, weeks 5– 8).
Eight-week treatment cycles were repeated for up to three
courses unless progression of disease occurred. Patients with an
unchanged tumour response in cycle two did not receive a
subsequent third treatment cycle.
Re-evaluation of the patients tumour status was performed
between treatment cycles. Arm A, B, C, and D patients received
a mean of 1.6, 1.6, 1.5, and 1.6 8-week cycles, respectively (range
1–6). Concomitant medication was given as needed to control
adverse effects of chemoimmunotherapy. Sixty patients (15.8%)
(arm A: 14%; arm B: 9.2%; arm C: 21.6%; arm D: 15%) did not
complete cycle one owing to early disease progression before the
first evaluation (2.9%), intolerance (8.7%), death during therapy
(1.6%), patients’ wish (2.1%), and non-compliance (0.5%),
respectively. Less than 4% of patients required in-patient care
throughout treatment. All patients were seen at regular weekly or
bi-weekly intervals by oncologic specialists; additional care was
provided whenever needed.
Assessment of response, survival, and toxicity
Response to therapy was evaluated according to World Health
Organization (WHO) criteria on an intent-to-treat basis. All
responses were reviewed by Board-certified expert radiologists.
In case of progression upon first re-evaluation after 8 weeks of
treatment, progression-free survival (PFS) was calculated at 0
months. Survival was measured from start of therapy to date of
death or to the last known date to be alive. All patients had to be
followed up for survival for at least 3 years as cutoff.
Systemic maximum toxicity was evaluated using a grading
system adapted from the WHO.
Statistical analysis
The statistical end points in our analysis were (1) OS, (2) PFS, and
(3) objective response of patients. The probability of OS and PFS
was plotted over time according to the method of Kaplan
and Meier (1958). Statistical significance was assessed using the
log-rank test.
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The 3-year survival rates were hypothesised to show a 20%
advantage of arm B over arm A (40 vs 20%), and a 15% advantage
of arm D over arm C (30 vs 15%). Using an a of 0.05 (one-sided), a
sample size of 64 patients each (arm A and arm B) and 95 patients
each (arm C and arm D) was needed to have 80% power to
statistically establish the assumed difference in 3-year survival
rates. To meet these statistical end points, randomisation was
performed 1 : 1 for groups I and II, respectively.
RESULTS
A total of 379 metastatic renal carcinoma patients were treated: 143
group I patients with pulmonary metastases (median OS: 21
months) were randomised to receive sc-IL-2, sc-IFN-a2a, and po-
13cRA (arm A); or arm A plus inhaled-IL-2 (arm B); 236 group II
patients (median OS: 17 months) were randomised to receive arm
A plus iv-5-FU (arm C); or arm A plus po-Capecitabine (arm D).
one, but received  
°sc-IL-2 = subcutaneous interleukin-2; sc IFN-2a = subcutaneous interferon-2a; p.o.-13cRA =
fluorouracil; p.o.-Capecit. = peroral Capecitabine
*Initial stratification was performed according to clinical characteristics.
peroral 13-cis-retinoic acid; inhaled-IL-2 = inhaled interleukin-2; i.v.-5-FU = intravenous 5-
Pre-treatment evaluation
Re-evaluation 
after 8-week cycle
78 patients received 
sc-IL-2/sc-IFN-2a/
p.o.-13cRA°
po-13cRA°
64 patients continued 
sc-IL-2/sc-IFN-2a/
po-13cRA/po-Capecit.°
treatment for up to
three 8-week cycles unless
progression occurred
51 patients continued 
sc-IL-2/sc-IFN-2a/
treatment for up to
three 8-week cycles unless
progression occurred
37 patients continued 
sc-IL-2/sc-IFN-2a/
treatment for up to
three 8-week cycles unless
progression occurred
52 patients continued 
sc-IL-2/sc-IFN-2a/
treatment for up to
three 8-week cycles unless
progression occurred
DBA
PDPDPD PD
CR/PR/SD CR/PR/SD CR/PR/SD
65 patients received 
sc-IL-2/sc-IFN-2a/
p.o.-13cRA/inhaled-IL-2°
116 patients received 
sc-IL-2/sc-IFN-2a/
p.o.-13cRA/iv-5-FU°
120 patients received 
sc-IL-2/sc-IFN-2a/
p.o.-13cRA/po-Capecit.°
C
po-13cRA/iv-5-FU°po-13cRA/inhaled-IL-2°
CR/PR/SD
 
143 patients randomised to arm A or B
379 patients were stratified*
236 patients randomised to arm C or D
38 patients 
complete cycle 
one, but received  
no further arm 
D therapy during to 
massive disease 
progression
18 patients did
not complete 
cycle 1
39 patients 
complete cycle 
no further arm 
C therapy during to 
massive disease 
progression
25 patients did
not complete 
cycle 1
22 patients 
complete cycle 
one, but received  
no further arm 
B therapy during to 
massive disease 
progression
6 patients did
not complete 
cycle 1
16 patients 
complete cycle 
one, but received  
no further arm 
A therapy during to 
massive disease 
progression
11 patients did
not complete 
cycle 1
Figure 1 Trial profile.
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Treatment response
Eight arm A (sc-IL-2/sc-IFN-a2a/po-13cRA) treated patients (10%)
achieved a complete response and 15 patients (19%) had a partial
remission (Table 2). The overall objective response rate was 29%
(95% CI 19, 40). Twenty-eight patients (36%) showed disease
stabilisation and 27 patients (35%) exhibited continuous disease
progression despite therapy.
In arm B (arm A plus inhaled-IL-2), there were eight complete
responders (12%) and 12 partial responders (19%), with an overall
objective response rate of 31% (95% CI 20, 44). Seventeen patients
(26%) had disease stabilisation, and in 28 patients (43%) a
continuous disease progression was observed.
In arm C (arm A plus iv-5-FU), four patients (3%) achieved a
complete response and 18 patients (16%) had a partial remission.
The overall objective response rate was 19% (95% CI 13, 27).
Thirty patients (26%) showed disease stabilisation and 64 patients
(55%) exhibited continuous disease progression despite therapy.
Nine arm D (arm A plus po-Capecitabine) treated patients (7%)
achieved a complete response and 23 patients (19%) had a partial
remission. The overall objective response rate was 26% (95% CI 19,
35). Thirty-two patients (27%) showed disease stabilisation, and in
56 patients (47%) a continuous disease progression was observed.
Progression-free survival
Seven patients (9%) in arm A (sc-IL-2/IFN-a2a/po-13cRA), six
patients (9%) in arm B (arm A plus inhaled-IL-2), five patients
(4%) in arm C (arm A plus iv-5-FU), and nine patients (8%) in arm
D (arm A plus po-Capecitabine) remained progression-free at last
follow-up. Patients reached a median PFS of 5 months in arm A
(3-year PFS: 8.8%) and 4 months in arm B (3-year PFS: 10.8%).
Median PFS was 0 months in arm C (3-year PFS: 7.8%) and 4
months in arm D (3-year PFS: 9.3%) (Figure 2). There was no
statistically significant difference in PFS between arms A and B
(P¼ 0.9837), and between arms C and D (P¼ 0.3265).
Overall survival
Seventeen patients (22%) in arm A (sc-IL-2/sc-IFN-a2a/po-
13cRA), 13 patients (20%) in arm B (arm A plus inhaled-IL-2),
16 patients (14%) in arm C (arm A plus iv-5-FU), and 22 patients
(18%) in arm D (arm A plus po-Capecitabine) continued to be
alive at last follow-up. Median OS was 22 months in arm A (3-year
OS: 29.7%), 18 months in arm B (3-year OS: 29.2%), 18 months in
arm C (3-year OS: 25.7%), and 16 months in arm D (3-year OS:
Table 1 Patients characteristics and pretreatment
Therapya
Characteristic Arm A Arm B Arm C Arm D
All
patients
Entered 78 65 116 120 379
Age (years)
Median 61 60 60 60 60
Range 28–79 42–75 32–78 35–75 28–79
Sex
Male 52 48 82 93 275
Female 26 17 34 27 104
Pretreatment
Radical tumour nephrectomy 70 57 107 109 343
Radiotherapy 7 6 19 19 51
Chemotherapy 2 2 3 4 11
Immunotherapy 2 3 4 9 18
Chemoimmunotherapy 3 4 4 8 19
Naturopathic 0 0 0 2 2
Others 1 1 5 0 7
Metastatic sites
Lung/pleural 78 65 57 70 270
Lymph nodes 28 13 42 46 129
Bone 8 12 28 32 80
Liver 6 6 29 28 69
Contralateral kidney 5 3 10 8 26
Adrenals 3 2 5 7 17
Soft tissue 2 0 10 11 23
CNS 0 0 4 1 5
Othersb 9 4 22 12 47
aArm A (sc-interleukin-2/sc-interferon-a2a/po-13-cis-retinoic acid); arm B (sc-
interleukin-2/sc-interferon-a2a/po-13-cis-retinoic acid/inhaled-IL-2); arm C (sc-inter-
leukin-2/sc-interferon-a2a/po-13-cis-retinoic acid/iv-5-fluorouracil); and arm D (sc-
interleukin-2/sc-interferon-a2a/po-13-cis-retinoic acid/po-Capecitabine). bIncluding
local relapse, thyroid, spleen, dermal, mammae.
Table 2 Response to therapy according to WHO criteria (intent to treat)
Response
Therapy Complete response Partial response Stable disease Progressive disease Total
Arm A
sc-interleukin-2/sc-interferon-a2a/ n 8 15 28 27 78
po-13-cis-retinoic acid % 10% 19% 36% 35% 100%
Obj. Resp. (95% CI) 29% (19–40%)
Arm B
sc-interleukin-2/sc-interferon-a2a/ n 8 12 17 28 65
po-13-cis-retinoic acid/inhaled-interleukin-2 % 12% 19% 26% 43% 100%
Obj. Resp. (95% CI) 31% (20–44%)
Arm C
sc-interleukin-2/sc-interferon-a2a/ n 4 18 30 64 116
po-13-cis-retinoic acid/iv-5-fluorouracil % 3% 16% 26% 55% 100%
Obj. Resp. (95% CI) 19% (13–27%)
Arm D
sc-interleukin-2/sc-interferon-a2/ n 9 23 32 56 120
po-13-cis-retinoic acid/po-Capecitabine % 7% 19% 27% 47% 100%
Obj. Resp. (95% CI) 26% (19–35%)
IL-2/IFN-a2a/13-RA-based chemoimmunotherapy in advanced RCC
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32.6%) (Figure 3). There was no statistically significant difference
in OS between arms A and B (P¼ 0.3387), and between arms C and
D (P¼ 0.5652).
Treatment toxicity
All four sc-IL-2/sc-IFN-a2a/po-13-cRA-based therapies were mod-
erately tolerated and could be administered in the outpatient
setting. Most side effects were limited to WHO grades I and II, and
no toxic deaths occurred. All toxicities reversed spontaneously
following completion of chemoimmunotherapy.
Table 3 summarises all grade I/II and III/IV treatment-related
adverse effects. More than 5% of patients experienced grade III or
IV treatment-related anorexia (24% arm A, 26% arm B, 18% arm
C, 26% arm D), malaise (19% arm A, 8% arm B, 11% arm C, 28%
arm D), nausea/vomiting (10% arm B), chills (9% arm C, 7% arm
D), fever (9% arm D), and respiratory distress (7% arm A, 7% arm
C).
A total of 5% of arm A (sc-IL-2/IFN-a2a/po-13-cRA), 8% of arm
B (arm A plus inhaled-IL-2), 12% of arm C (arm A plus iv-5-FU),
and 8% of arm D (arm A plus po-Capecitabine) patients
discontinued treatment owing to toxicity.
DISCUSSION
In this prospectively randomised trial, we reported the results of
379 patients with progressive metastatic renal cell carcinoma who
received (A) sc-IL-2, sc-IFN-a2a, po-13cRA, (B) arm A plus
inhaled-IL-2, (C) arm A plus iv-5-FU, or (D) arm A plus po-
Capecitabine.
We showed that patients with lung metastases, an erythrocyte
sedimentation rate p70 mm h1, and neutrophil counts
p6000 ml1 (group I) achieved a median OS of 22 months (arm
A) and 18 months (arm B), whereas all other patients (group II)
reached a median OS of 18 months (arm C) and 16 months (arm
D), with no statistically significant differences. Overall, other
authors reported a median OS of 17 months (sc-IL-2/sc-IFN-a/
po13-cRA) (Stadler et al, 1998), 19 months (sc-IL-2/sc-IFN-a/
inhaled-IL-2) (Huland et al, 1994), and 11–27 months (sc-IL-2/sc-
IFN-a/po-13cRA/iv-5-FU) (Soori et al, 2002; Atzpodien et al, 2004).
It should be noted that the primary end point of the current trial
was not reached, given 3-year OS-rates of 29.7% (arm A) and
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Progression−free survival
Kaplan−Meier Estimates
Months
P
A vs B 
P = 0.9837
C vs D
P = 0.3265
No.of patients at risk
A   78   19 12 6 6 5 2 −
B 65   18 10 7 5 5 0 −
C 116   22 13 9 7 5 2 −
D   120    27 18 11 10  8 3 −
Figure 2 Progression-free survival: Kaplan–Meier estimates. Arm A, sc-
IL-2, sc-IFN-a2a, po-13-cis-retinoic acid; n¼ 78; median PFS, 5 months;
3-year PFS, 8.8%. Arm B, sc-IL-2, sc-IFN-a2a, po-13-cis-retinoic acid,
inhaled-IL-2; n¼ 65; median PFS, 4 months; 3-year PFS, 10.8%. Arm C,
sc-IL-2, sc-IFN-a2a, po-13-cis-retinoic acid, iv-5-FU; n¼ 116; median PFS,
0 months; 3-year PFS, 7.8%. Arm D, sc-IL-2, sc-IFN-a2a, po-13-cis-retinoic
acid, po-Capecitabine; n¼ 120; median PFS, 4 months; 3-year PFS, 9.3%.
96847260483624120
0.0
0.2
0.4
0.6
0.8
P
1.0
B
A
C
A vs B 
P = 0.3387
C vs D
P = 0.5652
D
Overall survival
Kaplan−Meier Estimates
Months
No. of patients at risk
A 75   58 37 22 19 13  6  −
B 65   46 26 19 13 11  3  −
C 116   75 41 29 19 13  4  −
D 120    74 45 38 22 14  6  −
Figure 3 Overall survival: Kaplan–Meier estimates. Arm A, sc-IL-2, sc-
IFN-a2a, po-13-cis-retinoic acid; n¼ 78; median OS, 22 months; 3-year OS,
29.7%. Arm B, sc-IL-2, sc-IFN-a2a, po-13-cis-retinoic acid, inhaled-IL-2;
n¼ 65; median OS, 18 months; 3-year OS, 29.2%. Arm C, sc-IL-2, sc-IFN-
a2a, po-13-cis-retinoic acid, iv-5-FU; n¼ 116; median OS, 18 months;
3-year OS, 25.7%. Arm D, sc-IL-2, sc-IFN-a2a, po-13-cis-retinoic acid,
po-Capecitabine; n¼ 120; median OS, 16 months; 3-year OS, 32.6%.
Table 3 Systemic maximum toxicity
% Patients
Arm Aa Arm Ba Arm Ca Arm Da
I/II III/IV I/II III/IV I/II III/IV I/II III/IV
Feverb 76 2 67 4 77 4 74 9
Chills 69 5 61 4 68 9 67 7
Malaise 60 19 67 8 77 11 59 28
Nausea/vomiting 60 2 52 10 70 5 58 2
Anorexia 48 24 35 26 44 18 44 26
Diarrhoea 33 — 29 5 38 4 38 2
Respiratory distress 41 7 48 4 41 7 39 4
Mucositis 52 2 48 4 46 2 45 —
Hypotension 38 — 19 — 23 2 23 —
Alopecia 3 — 36 — 23 2 28 —
Arrythmias 24 2 10 — 12 4 13 2
CNS/disorientation 26 — 19 — 22 — 26 2
Paresthesias 21 — 5 — 11 — 12 —
Fluid retention/oedema 12 — 14 — 5 2 13 2
Leucocyte counts 10 2 6 3 12 — 6 2
Thrombocyte counts 4 — — — 3 — 8 2
Haemoglobin levels 16 — 14 5 31 2 21 5
aArm A (sc-interleukin-2/sc-interferon-a2a/po-13-cis-retinoic acid); arm B (sc-
interleukin-2/sc-interferon-a2a/po-13-cis-retinoic acid/inhaled-IL-2); arm C (sc-inter-
leukin-2/sc-interferon-a2a/po-13-cis-retinoic acid/iv-5-fluorouracil); and arm D (sc-
interleukin-2/sc-interferon-a2a/po-13-cis-retinoic acid/po-Capecitabine). bAll patients
received a standard regimen of fever-reducing treatment employing p.o. paracetamol.
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29.2% (arm B) in group I, and 25.7% (arm C) and 32.6% (arm D)
in group II, with no statistically significant differences.
There were also no significant differences in PFS and objective
response between arms A (sc-IL-2/sc-IFN-a/po-13cRA) and B (arm
A plus inhaled-IL-2), and between arms C (arm A plus iv-5-FU)
and D (arm A plus po-Capecitabine). Inhaled IL-2 in poor-risk
patients unfit for systemic cytokine therapy has been reported to
induce remarkable effects on lung metastases leading to objective
responses between 2.5–21% (inhaled-IL-2) (Lorenz et al, 1996;
Merimsky et al, 2004) and 47% (inhaled-IL-2/10% sc-IL-2/INFa)
(Huland et al, 1994). In this multicentre trial, inhaled-IL-2 (arm B)
at a dose 5.3-fold the subcutaneous (sc) dose did not significantly
enhance treatment efficacy when compared to arm A. However,
there are major differences compared with other reports using
inhaled-IL-2 in patient selection, complementary therapy, dose
distribution, and treatment time. In this trial, we treated patients
with good performance status in addition to an effective systemic
chemoimmunotherapy, where further improvement of objective
responses may be unlikely. We used inhalation for a mean of 1.6
cycles or 64 inhalation days compared to mean treatment times of
260 inhalation days (301 days in total) reported in poor-risk patients
earlier (Huland et al, 2003). Our results confirmed safety and
tolerance of inhaled-IL-2 added to effective chemoimmunotherapy.
Although the use of po-Capecitabine (arm D), as 5-FU pro-drug,
yielded objective response rates of 34% in preliminary studies
(Oevermann et al, 2000), here, it did not significantly impact
on objective response rates and survival when compared to arm C
(sc-IL-2/sc-IFN-a2a/po-13cRA/iv-5-FU). However, with compar-
able safety and tolerance, the oral application of Capecitabine
presented a potential treatment improvement in the palliative
setting.
In the present trial, all four treatment arms were moderately
tolerated; yet, more than 5% of patients experienced grade III or IV
treatment-related side effects, notably, anorexia and malaise. It was
previously suggested that grade III and IV toxicities and reduced
quality of life may be more prevalent in a po-13cRA-based
treatment (Motzer et al, 2000; Atzpodien et al, 2004; Aass et al,
2005). Here, the observed antitumour effects of po-13cRA must be
weighed against the toxicity profile in patients with metastatic
renal cell carcinoma.
In summary, given the known therapeutic efficacy of sc-IL-2/sc-
INF-a2a/po-13cRA-based outpatient chemoimmunotherapies, our
results did not establish survival advantages in favour of po-
Capecitabine vs iv-5-FU, and in favour of short-term inhaled-IL-2
in patients with advanced renal cell carcinoma receiving systemic
cytokines.
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